Compare Sana Biotechnology Inc (SANA) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs S&P500 ETF — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while S&P500 ETF trades at $778.54 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 981.9× Sana Biotechnology Inc's market cap, and S&P500 ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and S&P500 ETF for 205 Days on average.
| SANA | SPY | |
|---|---|---|
Market Cap | $836.71M | $821.54B |
Volume | 4,507,444 | 40,070,358 |
Sector | Health | — |
52-Week High | $5.92 | $779.14 |
52-Week Low | $2.68 | $631.99 |
Typical Hold Time | 23 Days | 205 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
SPY, tracking the S&P 500, trades at $773.97, down 0.42% on the day amid mixed market signals. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. The ETF's fundamentals are tied to the broad U.S. equity market, with no specific company financials available, and a future dividend of $1.89 scheduled for October 2026. Recent news highlights concerns over valuation and profit growth expectations for 2027.
The outlook for SPY is cautiously optimistic, driven by bullish technical trends and seasonal patterns, but risks include potential earnings growth slowdown and elevated market valuations. Investors may find opportunity in broad market exposure, though vigilance on macroeconomic indicators and corporate profit trends is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
